Zealand Pharma A/S

Zealand Pharma A/S maintains a strong liquidity position, with a current ratio of 23.57 and cash and equivalents of DKK 4.58 billion, which significantly exceeds its total liabilities of DKK 1.12 billion. The company's liquidity_fpt score is high, indicating a robust ability to meet short-term obligations without reliance on external financing. Profitability metrics are strong, with a return on equity (ROE) of 43.52% and a return on assets (ROA) of 40.47%, both well above the industry median for biotechnology firms. The company's operating margin is effectively 75.5%, as operating income of DKK 6.96 billion represents 75.5% of total revenue of DKK 9.21 billion, indicating efficient cost management and high gross margin retention. Zealand Pharma A/S operates as a single business segment, with all revenue derived from its core biotechnology operations. The company is headquartered in Denmark and has no material geographic diversification, with all revenue generated from global markets. This lack of geographic diversification may expose the company to regional regulatory or economic risks. The company's growth trajectory is positive, with a strong current year revenue of DKK 9.21 billion and a free cash flow of DKK 6.41 billion. While no specific forward-looking revenue guidance is provided, the company's operating cash flow and free cash flow suggest a capacity for reinvestment or shareholder returns. The outlook for the next fiscal year is not explicitly provided, but the company's strong cash position supports continued R&D investment. Risk factors for Zealand Pharma A/S are minimal in the short term, with low liquidity and dilution risk scores. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is supported by a low debt-to-equity ratio of 0.03. The company has not issued new shares in the recent period, and there is no indication of near-term dilution pressure. Recent events include strong analyst sentiment, with a mean price target of DKK 554.40 and a median price target of DKK 500.00. The company has received 4 strong-buy ratings, 9 buy ratings, and 5 hold ratings, indicating a generally positive outlook from the investment community. No recent filings or transcripts have been identified that would suggest a material change in the company's strategic direction or financial health.